Utilization of Educational Interventions in Completion of Genetic Testing in Black Patients With High-Risk Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18 lat lub starsi
- •Mężczyźni identyfikujący się rasowo jako czarnoskórzy lub wielorasowi (w tym czarnoskórzy)
- •Diagnoza raka prostaty
- •Niskie, pośrednie lub wysokie ryzyko raka prostaty z rodzinną historią choroby lub szczególnym typem komórek rakowych
- •Rak prostaty wysokiego ryzyka, bardzo wysokiego ryzyka, z przerzutami do węzłów chłonnych lub rozprzestrzeniony
✗ Disqualifies
- •Wcześniejsze wykonanie testu genetycznego
- •Pozytywny wynik testu genetycznego komórek nowotworowych sugerujący wariant genetyczny
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 15, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Henry Ford Cancer Pavilion
Detroit, United States
Trial contact
Clara Hwang, MD
Karthik Subramanian, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.